Yale University

Hepatic safety and antiretroviral effectiveness in HIV-infected patients receiving naltrexone.

TitleHepatic safety and antiretroviral effectiveness in HIV-infected patients receiving naltrexone.
Publication TypeJournal Article
Year of Publication2012
AuthorsTetrault, Jeanette M., Janet P. Tate, Kathleen A. McGinnis, Joseph L. Goulet, Lynn E. Sullivan, Kendall Bryant, Amy C. Justice, and David A. Fiellin
Corporate AuthorsVeterans Aging Cohort Study Team
JournalAlcoholism, clinical and experimental research
Volume36
Issue2
Pagination318-24
Date Published2012 Feb
ISSN1530-0277
KeywordsAdult, Aged, Alanine Transaminase, Alcoholism, Antiretroviral Therapy, Highly Active, Aspartate Aminotransferases, CD4 Lymphocyte Count, Cohort Studies, Databases, Factual, Drug Interactions, Drug Toxicity, Drug-Induced Liver Injury, Female, HIV Infections, Humans, Liver, Liver Function Tests, Male, Middle Aged, Naltrexone, Narcotic Antagonists, Opioid-Related Disorders, RNA, Viral, Veterans
AbstractWe sought to determine the impact of naltrexone on hepatic enzymes and HIV biomarkers in HIV-infected patients.
DOI10.1111/j.1530-0277.2011.01601.x
Alternate JournalAlcohol. Clin. Exp. Res.

External Links